|Slideshows|June 5, 2018

Geriatric Psychiatry Research Update: June 2018

Three new studies examine research on biomarkers to predict lifetime risk of Alzheimer disease; diet and brain tissue volume; and cognitive impairment in active older adults.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Week in Review: October 20-24

ByJessica Walters

October 24th 2025

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

ByAmita R. Patel, MD, CMD, MHA, CPE

October 23rd 2025

Rights and Risks in Geriatric Capacity Assessment

ByKaren Reimers, MD

October 22nd 2025

Insomnia in Older Adults: A Holistic Approach

ByEbony Dix, MD,Shilpa Srinivasan, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

October 21st 2025

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

BySehba Husain-Krautter MD, PhD,James M. Ellison, MD, MPH

October 20th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Geriatric Psychiatry Research Update: June 2018

Newsletter

Related Content

Week in Review: October 20-24

Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings

Rights and Risks in Geriatric Capacity Assessment

Insomnia in Older Adults: A Holistic Approach

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled